Therefore, on the basis of our results of increased vascular permeability caused by DPP4-inhibitor, GLP-1 agonists might have an advantage over DPP4-inhibitors in terms of concern about aggravation of diabetic retinopathy. This evidence concerns the gene GLP1R and diabetic retinopathy.